Schmidt P J Investment Management Inc. Has $7.34 Million Holdings in Stryker Co. (NYSE:SYK)

Schmidt P J Investment Management Inc. boosted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 19.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,561 shares of the medical technology company's stock after acquiring an additional 3,883 shares during the quarter. Stryker comprises 1.5% of Schmidt P J Investment Management Inc.'s investment portfolio, making the stock its 19th biggest holding. Schmidt P J Investment Management Inc.'s holdings in Stryker were worth $7,336,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Fairfield Bush & CO. acquired a new position in shares of Stryker during the first quarter worth about $131,000. Dimensional Fund Advisors LP boosted its holdings in Stryker by 1.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 673,924 shares of the medical technology company's stock valued at $180,182,000 after purchasing an additional 9,026 shares in the last quarter. Prudential PLC acquired a new position in Stryker during the 1st quarter worth approximately $1,444,000. Sequoia Financial Advisors LLC raised its stake in shares of Stryker by 21.6% during the 1st quarter. Sequoia Financial Advisors LLC now owns 3,056 shares of the medical technology company's stock worth $817,000 after buying an additional 543 shares in the last quarter. Finally, Zions Bancorporation N.A. raised its stake in shares of Stryker by 9.2% during the 1st quarter. Zions Bancorporation N.A. now owns 3,140 shares of the medical technology company's stock worth $839,000 after buying an additional 265 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 3,273 shares of the company's stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares of the company's stock, valued at $1,287,633,391.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the business's stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares of the company's stock, valued at $4,856,522. The disclosure for this sale can be found here. Insiders have sold a total of 212,109 shares of company stock valued at $72,845,768 in the last quarter. 5.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. TD Cowen upped their price objective on Stryker from $365.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday. Canaccord Genuity Group raised shares of Stryker from a "hold" rating to a "buy" rating and set a $360.00 price target on the stock in a research note on Wednesday, January 31st. Canaccord Genuity Group upgraded shares of Stryker from a "hold" rating to a "buy" rating and raised their price objective for the company from $315.00 to $360.00 in a research note on Wednesday, January 31st. Wells Fargo & Company boosted their price objective on shares of Stryker from $336.00 to $364.00 and gave the stock an "overweight" rating in a report on Wednesday, January 31st. Finally, Citigroup increased their target price on shares of Stryker from $362.00 to $406.00 and gave the company a "buy" rating in a report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $338.09.

Stryker Price Performance

Shares of NYSE:SYK traded down $4.24 on Friday, hitting $342.05. The company had a trading volume of 1,009,550 shares, compared to its average volume of 1,256,899. The company has a market cap of $130.14 billion, a PE ratio of 41.97, a PEG ratio of 2.80 and a beta of 0.89. The business has a 50 day moving average of $350.82 and a 200 day moving average of $310.00. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. The company had revenue of $5.82 billion for the quarter, compared to analysts' expectations of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm's revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period last year, the company earned $3.00 EPS. As a group, equities analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 annualized dividend and a yield of 0.94%. Stryker's dividend payout ratio (DPR) is presently 38.79%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.